RT Journal Article
SR Electronic
T1 Single-cell genomics improves the discovery of risk variants and genes of Atrial Fibrillation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.02.22270312
DO 10.1101/2022.02.02.22270312
A1 Alan Selewa
A1 Kaixuan Luo
A1 Michael Wasney
A1 Linsin Smith
A1 Xiaotong Sun
A1 Chenwei Tang
A1 Heather Eckart
A1 Ivan P. Moskowitz
A1 Anindita Basu
A1 Xin He
A1 Sebastian Pott
YR 2023
UL http://medrxiv.org/content/early/2023/02/27/2022.02.02.22270312.abstract
AB Genome-wide association studies (GWAS) have linked hundreds of loci to cardiac diseases. However, in most loci the causal variants and their target genes remain unknown. We developed a combined experimental and analytical approach that integrates single cell epigenomics with GWAS to prioritize risk variants and genes. We profiled accessible chromatin in single cells obtained from human hearts and leveraged the data to study genetics of Atrial Fibrillation (AF), the most common cardiac arrhythmia. Enrichment analysis of AF risk variants using cell-type-resolved open chromatin regions (OCRs) implicated cardiomyocytes as the main mediator of AF risk. We then performed statistical fine-mapping, leveraging the information in OCRs, and identified putative causal variants in 122 AF-associated loci. Taking advantage of the fine-mapping results, our novel statistical procedure for gene discovery prioritized 46 high-confidence risk genes, highlighting transcription factors and signal transduction pathways important for heart development. In summary, our analysis provides a comprehensive map of AF risk variants and genes, and a general framework to integrate single-cell genomics with genetic studies of complex traits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by National Institutes of Health (NIH) grants, R01MH110531 and R01HG010773 (to X.H.), R01HL163523 (to X.H., S.P., and I.P.M.), and R21 AI144417-02 (to O.B). This project has been made possible in part by grant number CZF2019-002431 from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Heart tissue samples were obtained from National Disease Research Interchange (NDRI) without identifying information. The work with these samples was determined to be Non-Human subject research and approved by the IRB committee of the University of Chicago (IRB19-1429).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur snRNA-seq and scATAC-seq data has been deposited in GEO repository: accession GSE224997. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE224997